Výsledky vyhledávání - "K M, Pisters"

Ifosfamide Plus High-Dose Cisplatin in Patients with Non-Small Cell Lung Cancer Previously Treated with Chemotherapy

Autor: V A, Miller, J R, Rigas, K M, Pisters, S C, Grant, D G, Pfister, R T, Heelan, M G, Kris

Publikováno v: American Journal of Clinical Oncology. 18:303-306

This study determined the maximum tolerated dose (MTD) of ifosfamide that could be given with high-dose cisplatin to non-small cell lung cancer (NSCLC) patients previously treated with non-platin-containing chemotherapy and to assess the efficacy of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743be24ae3fc50b0f3b3845ce3776190
https://doi.org/10.1097/00000421-199508000-00007

Zobrazit plný text záznamu

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin

Autor: S A, Laurie, D G, Pfister, M G, Kris, W P, Tong, G, Chronowski, K M, Pisters, R T, Heelan, F M, Sirotnak

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(3)

The antifolate edatrexate has shown moderate activity against cancers of the head and neck and non-small cell lung cancer, as has cisplatin. Edatrexate demonstrates synergy with cisplatin in transplanted tumor models. This Phase I study was designed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e9f9d12637404f78afefc7a87f85745e
https://pubmed.ncbi.nlm.nih.gov/11297240

Zobrazit plný text záznamu

Treatment of stage I lung cancer

Autor: G L, Walsh, K M, Pisters, C, Stevens

Publikováno v: Chest surgery clinics of North America. 11(1)

This article reviews changes in the roles of surgeons, medical oncologists, and radiation oncologists that have occurred over the past 20 years. A gradual evolution will certainly continue over the next several decades in the multidisciplinary quest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::52792e04c2376a6c1b01af11270c89c0
https://pubmed.ncbi.nlm.nih.gov/11253597

Zobrazit plný text záznamu

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team

Autor: K M, Pisters, R J, Ginsberg, D J, Giroux, J B, Putnam, M G, Kris, D H, Johnson, J R, Roberts, J, Mault, J J, Crowley, P A, Bunn

Publikováno v: The Journal of thoracic and cardiovascular surgery. 119(3)

This phase II trial assessed the feasibility, as measured by response rate, toxicity, resectability rate, and surgical morbidity and mortality rates, of perioperative paclitaxel and carboplatin chemotherapy in patients with early-stage non-small cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a02706eb7bce9d49f0a55e43f66d58a2
https://pubmed.ncbi.nlm.nih.gov/10694600

Zobrazit plný text záznamu

Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma

Autor: K K, Ng, M G, Kris, R J, Ginsberg, R T, Heelan, K M, Pisters, V A, Miller, S C, Grant, M, Bains, V, Rusch, K E, Rosenzweig, N, Martini

Publikováno v: Cancer. 86(7)

Cisplatin-based induction chemotherapy before surgery or irradiation has improved the survival of patients with Stage III nonsmall cell lung carcinoma (NSCLC). Encouraged by earlier results with preoperative MVP (cisplatin [120 mg/m(2) or 25 mg/m(2)/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7591b2e2f2d4d788ea5551faa4393aeb
https://pubmed.ncbi.nlm.nih.gov/10506703

Zobrazit plný text záznamu

Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team

Autor: K M, Pisters, M G, Kris, P A, Bunn, D H, Johnson, J C, Ruckdeschel, J J, Crowley, R J, Ginsberg

Publikováno v: Seminars in oncology. 24(4 Suppl 12)

In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::56819b4cdc661840584bbc9abd4a696a
https://pubmed.ncbi.nlm.nih.gov/9331120

Zobrazit plný text záznamu

Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report

Autor: J S, Lee, K M, Pisters, R, Komaki, B S, Glisson, F R, Khuri, R, Schea, F V, Fossella

Publikováno v: Seminars in oncology. 24(4 Suppl 12)

Chemotherapy has been rarely considered an important treatment modality for brain metastases. Based on the hypothesis that the lack of efficacy of chemotherapy, rather than the blood-brain barrier itself, may be the major hindrance to the successful

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3dd04ab6c93fc41f85f889ac913e5638
https://pubmed.ncbi.nlm.nih.gov/9331122

Zobrazit plný text záznamu

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer

Autor: K M, Pisters, L B, Tyson, W, Tong, M, Fleisher, V A, Miller, S C, Grant, D G, Pfister, J R, Rigas, C L, Densmore, G, Krol, R T, Heelan, F M, Sirotnak, J R, Bertino, M G, Kris

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 2(11)

Our objective was to determine the maximum tolerated dose and toxicity of i.v. edatrexate with p.o. leucovorin. Thirty-one adults with advanced solid tumors received edatrexate as a 2-h infusion, once a week for 3 weeks, recycled every 28 days. p.o.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e434c566a8b4fcc05e5c915ad09633da
https://pubmed.ncbi.nlm.nih.gov/9816135

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání